Want to see INDP full AI Analyst Report?
INDP Stock Chart & Stats
$2.72
-$0.06(-5.94%)
At close: 4:00 PM EST
$2.72
-$0.06(-5.94%)
Day’s Range― - ―
52-Week Range$0.92 - $13.40
Previous CloseN/A
Volume47.54K
Average Volume (3M)1.08M
Market Cap
$343.12M
Enterprise Value$6.38M
Total Cash (Recent Filing)$1.50M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.34
Shares Outstanding113,242,325
10 Day Avg. Volume869,867
30 Day Avg. Volume1,084,648
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.89
Price to Sales (P/S)0.00
P/FCF Ratio-0.19
Enterprise Value/Market Cap0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe combination study of Decoy and tislelizumab is ongoing, with positive safety results so far, which is promising for the treatment of solid tumors.
Safety ProfileDecoy therapy uses a nonpathogenic strain of bacteria, reducing endotoxin levels significantly, which enhances its safety profile.
Therapeutic DevelopmentMaintain a Buy rating given the Decoy20 opportunity in solid tumors, which has shown positive safety data thus far.
Bears Say
Capital RequirementsIndaptus will need to raise additional capital to continue the clinical development of its Decoy immune therapy.
Financial PerformanceIndaptus reported 3Q25 results with a net loss of ($2.9M) and ended the period with $5.8M in cash on the balance sheet, which the company expects to provide runway into 1Q26.
Stock ValuationBased on near-term capital needs and expectations of additional dilution from future raises, the 12-month price target is lowered to $10, from $25.
Indaptus Therapeutics News
INDP FAQ
What was Indaptus Therapeutics’s price range in the past 12 months?
Indaptus Therapeutics lowest stock price was $0.92 and its highest was $13.40 in the past 12 months.
What is Indaptus Therapeutics’s market cap?
Indaptus Therapeutics’s market cap is $343.12M.
When is Indaptus Therapeutics’s upcoming earnings report date?
Indaptus Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 45 days.
How were Indaptus Therapeutics’s earnings last quarter?
Indaptus Therapeutics released its earnings results on May 15, 2026. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.23.
Is Indaptus Therapeutics overvalued?
According to Wall Street analysts Indaptus Therapeutics’s price is currently Overvalued.
Does Indaptus Therapeutics pay dividends?
Indaptus Therapeutics does not currently pay dividends.
What is Indaptus Therapeutics’s EPS estimate?
Indaptus Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Indaptus Therapeutics have?
Indaptus Therapeutics has 113,242,325 shares outstanding.
What happened to Indaptus Therapeutics’s price movement after its last earnings report?
Indaptus Therapeutics reported an EPS of -$0.23 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.143%.
Which hedge fund is a major shareholder of Indaptus Therapeutics?
Currently, no hedge funds are holding shares in INDP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Indaptus Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.47%
12-Months-Change
Fundamentals
Return on Equity
-1028.81%
Trailing 12-Months
Asset Growth
-59.70%
Trailing 12-Months
Company Description
Indaptus Therapeutics
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Technical Analysis
Palisade Bio
―
Alaunos Therapeutics
―
―
Xenetic Biosciences
―
Longevity Health Holdings
―
Ownership Overview
0.39% Insiders
<0.01% Mutual Funds
0.02% Other Institutional Investors
99.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---